



Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award

Mar 8 2024, 9:00 AM EST

Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair

Feb 22 2024, 8:00 AM EST

Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray

Jan 31 2024, 8:30 AM EST

Stock Overview

Symbol	KNE
Exchange	TSXV
Market Cap	13.18m
Last Price	\$0.10
52-Week	\$0.05 - \$0.14

03/12/2024 09:30 AM EDT

Investor Relations

Kane Biotech Inc.
Nicole Sendey
Investor Relations & Public
Relations
T: 204-453-1301
nsendey@kanebiotech.com

Board of Directors

Marc Edwards

President, Chief Executive Officer, Director

Dr. Robert Huizinga

Director

Georges Morin

Director

Philip Renaud

Director

Kane Biotech Inc.

290-100 Innovation Drive
Winnipeg, MB R3T 6G2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.